Issue 24, 2022

Monoglycocalix[4]arene-based nanoparticles for tumor selective drug delivery via GLUT1 recognition of hyperglycolytic cancers

Abstract

We have developed a new strategy of tumor-specific glucose transporter (GLUT)-mediated selective drug delivery using amphiphilic fluorescent monoglycocalix[4]arene in docetaxel (DTX) encapsulated nanoparticles (NPs) that leads to significant improvement in cytotoxic activity against a panel of human cancer cells. The fluorescent tracer conjugation in the calixarene enables the self-probed tumor targeting analysis and makes the system potentially suitable for tumor diagnostic imaging.

Graphical abstract: Monoglycocalix[4]arene-based nanoparticles for tumor selective drug delivery via GLUT1 recognition of hyperglycolytic cancers

Supplementary files

Article information

Article type
Communication
Submitted
07 Apr 2022
Accepted
30 May 2022
First published
30 May 2022

Org. Biomol. Chem., 2022,20, 4884-4887

Monoglycocalix[4]arene-based nanoparticles for tumor selective drug delivery via GLUT1 recognition of hyperglycolytic cancers

L. Zhang, S. Liu, Y. Li, M. Liang, H. Zhao and W. Yang, Org. Biomol. Chem., 2022, 20, 4884 DOI: 10.1039/D2OB00656A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements